NSEAnalysts/Institutional Investor Meet/Con. Call Updates1d ago · 17 Nov 2026, 06:29 pm

Analysts/Institutional Investor Meet/Con. Call Updates

Viyash Scientific Limited · VIYASH

✦ AI Summary▲ PositiveResults

Viyash Scientific Limited has informed the Exchange about the transcript of the Earnings Call held on November 14, 2026, for the Q2 FY27 Financial Results. The company has reported strong growth with double-digit growth for the fifth consecutive quarter, with strong margins and reducing debt. The company has also closed the acquisition of BioForLife effective from 1st October, and the results will be consolidated from Q3 FY27 onwards.

Analysis Scores

Earnings Impact8/10
Growth Catalyst9/10
Governance Concern1/10
Regulatory Risk2/10
Balance Sheet Risk1/10
Liquidity Impact9/10
Market Sentiment8/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Viyash Scientific Limited has informed the Exchange about Transcript

Attachments (1)

📄

SEQUENT2_17112026182841_SE_Intimation_Earnings_Transcript.pdf

pdf

Download →
View document text
Viyash Scientific Limited (Formerly known as Sequent Scientific Limited) Registered Office: 3rd Floor, Srivalli’s Corporate, Plot No.290, Road No.6, Sy.No.33, 34P to 39, Guttala Begumpet, Jubilee Hills, Hyderabad, Shaikpet, Telangana, India-500033 T: +91 40 23635000, E: investorrelations@viyash.com Website: www.viyash.com CIN: L99999TS1985PLC196357 November 17, 2026 BSE Limited N ational Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, Dalal Street, Fort, Bandra-Kurla Complex, Mumbai - 400 001 Bandra (East), Mumbai - 400 051 Scrip code: 512529 Symbol: VIYASH Dear Sir/ Madam, Subject: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Earnings Call Transcript Dear Sir/Madam, Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the transcript of the Earnings Call held on November 14, 2026, for the Q2 FY27 Financial Results. The same is also available on the Company’s website at: https://viyash.com/financial This is for your information and appropriate dissemination. Thanking you, Yours faithfully, For Viyash Scientific Limited (Formerly known as Sequent Scientific Limited) Yoshita Vora Company Secretary & Compliance Officer “Viyash Scientific Limited Q2 FY27 Earnings Conference Call” November 14, 2026 MANAGEMENT: DR. HARIBABU BODEPUDI – MANAGING DIRECTOR AND GROUP CHIEF EXECUTIVE OFFICER – VIYASH SCIENTIFIC LIMITED MR. RAJARAM NARAYANAN – EXECUTIVE DIRECTOR AND CHIEF EXECUTIVE OFFICER, ANIMAL HEALTH – VIYASH SCIENTIFIC LIMITED MR. RAMAKANT SINGANI – CHIEF FINANCIAL OFFICER – VIYASH SCIENTIFIC LIMITED Page 1 of 25 Viyash Scientific Limited November 14, 2026 Moderator: Ladies and gentlemen, good day and Welcome to the Viyash Scientific Limited Q2 FY27 Earnings Conference Call. As a reminder, all participant lines will be in the listen-only mode, and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during the conference call, please signal an operator by pressing star then zero on your touch-tone phone. I now hand the conference over to Mr. Abhishek Singhal. Thank you, and over to you. Abhishek Singhal Thank you, Nitya. A very good morning to all of you, and thank you for joining us today for Viyash Scientific Limited's earnings conference call for the second quarter and first half of financial year 2027, ended September 30, 2026. Today, we have with us Dr. Haribabu, Managing Director and Group CEO, Mr. Rajaram, Executive Director and CEO, Animal Health, and Mr. Ramakant, CFO of the company, to share the highlights of the business and financials for the quarter. I hope you have gone through our results release and the investor presentation, which have both been uploaded on our website as well as stock exchange.. The transcript for this call will be available in a week's time on the company's website. Please note that today's discussion will be forward-looking in nature and must be viewed in relation to the risks pertaining to our business. After the end of this call, in case you have any further questions, please feel free to reach out to the investor relation team. I now hand over the call to Dr. Haribabu to make his opening remarks. Haribabu Bodepudi: Thanks, Abhishek. Good morning, everyone. Welcome to Viyash Scientific investor call for Q2 FY27. Thanks for taking the time to join us today. Hope everyone had a good Diwali. I am very happy to share that Q2 FY27 continues to build on the previous quarters with strong growth. This is now the fifth consecutive quarter of double-digit growth with strong margins and reducing debt. I believe now we are in good shape with strong financial strength and diversified business, helping us perform better than earlier standalone entities. We have closed the acquisition of BioForLife effective from 1st October, and the results will be consolidated from Q3 FY27 onwards. Now, let me talk about the performance in various segments. First, to start with the consolidated level. For the first half of FY27, revenue stands at INR1,934 crores, up by 17.8% year-on-year. Pre- ESOP EBITDA is at INR 412 crores, up by 30% year-on-year, with EBITDA margin at 21.3%. Profit after tax, INR 164 crores, and up by 50% higher than last year. Adjusted PAT with normalized ESOP cost is at INR 204 crores. Cash flow from operations, we generated INR 182 crores from first half. Coming to the quarter two FY27, revenue is at INR 988 crores, up by 16.2% year-on-year, and pre-ESOP EBITDA is at INR 208 crores. Profit after tax was INR 85 crores, higher by 16% from last year. Adjusted PAT with normalized ESOP cost is at INR 110 crores. How we adjusted this ESOP cost? You know, last year and this year is merger and some exceptions on ESOP. Because of earlier ESOPs, whatever we allotted to employees, we have to honor those things. What you allotted versus the current price, we have to adjust that. There's a huge ESOP expenses Page 2 of 25 Viyash Scientific Limited November 14, 2026 coming out this year. We considered normal run rate about INR 20-25 crores per year. In this calculation, we considered from next year onwards, after first quarter FY28, normalized ESOP cost will be around INR 25 crores. We have taken out INR 25 crores run rate from INR 42 crores of last quarter and calculated tax, Indian tax, around 25-26%, and arrived INR 110 crores from that. Coming to the balance sheet level, net debt stands at INR 26 crores now, and net debt to LTM EBITDA is negligible now, down from 0.1x to zero almost last quarter, and 0.7x a year back. This is a direct result of strong operating performance and execution discipline we have spoken about over the last few calls. It gives us very strong base to pursue both our organic growth plans and inorganic opportunities. Coming to each segment performance. In formulation, Europe performance was led by strong volume growth across different countries. Emerging markets continue to show good growth numbers, led by strong volume growth in Brazil and volume as well as new product growth in Turkey. Indian formulation also witnessed strong growth across both own and distributed products. As you know, we distribute products for BI on companion animals. Let me now share status on few strategic areas, we have been working on animal health formulation: 1) Starting with BioForLife integration. As I mentioned earlier, we have successfully completed the acquisition of BioForLife, with consolidation effective from October 1, 2026. We have started working on geo-extension of first list of 10 products in the gastro, dermatology and ophthalmology ranges in various countries where we have already front- end presence, which includes some of the countries in Europe, Brazil, LATAM, Turkey, and India. As we move ahead with integration, we expect significant benefit from cross- selling BFL and Alivira products across their core geographies, plus a strong platform to launch our new companion animal products. We expect the benefits to start flowing in next two-three years. As I mentioned earlier, for any new products or any expansion into the new markets, registration will take 15 -18 months, even for existing products. Once you start building marketing, it takes another six-eight months. All these benefits we can start seeing from two to three years, on both sides, expanding BFL products as well as launching our Alivira products into Italy. 2) Coming to expansion into new geographies, We completed registration of our entity in Vietnam, and product registration has been started already, and we expect commercial sales to start from early next year. We are working on few more countries to expand our products and animal presence in next year. 3) Coming to the new products, which is very important for midterm as well as long term to achieve our aspirations. New products are very critical in that perspective. [Showing first 8,000 characters — download PDF for full document]